Bill & Melinda Gates Foundation

Likarda is a biotechnology company focused on developing innovative cell therapies and delivery technologies. Utilizing its patented Core-Shell Spherification® platform, Likarda specializes in cell encapsulation within biocompatible hydrogels, such as Hyaluronic Acid and PEG, which allows for customized delivery solutions tailored to the unique specifications of various cell therapies. The company's approach enables the creation of microcapsules that can provide injectable treatments with enhanced localization and efficacy or offer immunoprotective barriers for long-term cell transplants. Likarda is actively working on therapies for diabetes and osteoarthritis, including the delivery of islet-like cells for diabetes treatment and the slow-release injection of encapsulated stem cells for alleviating joint pain and reversing osteoarthritis degradation. The company has achieved significant recognition, including being named one of the "50 Most Promising Start-Ups in the World." To date, Likarda has secured over $8 million in funding through private investments, grants, and contract services.

Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

BioSurfaces is a developer of medical devices specializing in tissue engineering and personal care products. The company leverages advanced electrospinning technology to produce nanofibrous materials that facilitate controlled drug delivery and enhance healing at the implant site. By utilizing a room-temperature electrospinning process, BioSurfaces enables the integration of drug loading within each fiber, creating a reservoir for sustained drug release. This innovative approach allows for the creation of devices and coatings as thin as 10 micrometers, making it possible to treat diseases directly at the site of implantation. The company aims to provide next-generation solutions for the medical and personal care markets, focusing on improving patient outcomes through effective disease treatment and tissue regeneration.

Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Noze is a leader in digital odor perception technology, creating advanced solutions that replicate the human sense of smell. Their sophisticated digital nose utilizes a specialized sensor, developed with NASA technology, to detect and identify odors in various real-world environments. This technology collects and analyzes data through an AI engine, allowing healthcare providers to assess air quality, monitor chemical footprints, and potentially diagnose diseases based on breath-based odor biomarkers. By enabling real-time disease detection and routine health screenings with a single exhale, Noze aims to enhance human health and well-being while improving patient outcomes.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

Ethris GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative therapeutic solutions for diseases with unmet medical needs. The company has a focus on transcript therapeutics, particularly through its SNIM RNA platform, which offers a novel approach to treating various conditions by enabling the production of therapeutic proteins within the patient’s body. This platform presents an alternative to traditional recombinant protein and gene therapies, addressing a range of diseases, including rare and genetically predetermined conditions. Ethris also develops Magnetovax, a personalized tumor vaccine platform that utilizes magnetic fields for localized activation in tumors. The company has established strategic research collaborations with major pharmaceutical firms, enhancing its capabilities in regenerative medicine and therapeutic development. Founded in 2009, Ethris continues to advance its technologies to meet diverse medical needs.

Surf Bio is a preclinical biopharmaceutical company focused on developing innovative therapeutic solutions using a novel biotechnology platform. This platform centers around a next-generation surfactant designed to enhance drug effectiveness for a variety of medical conditions, including diabetes, oncology, infectious diseases, and gene therapy. By improving therapeutic applications, Surf Bio aims to provide healthcare organizations worldwide with access to new and more effective treatments for patients facing critical health issues.

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds (VOCs) in breath, serving as biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA, disease biomarker detection tools such as Lonestar, and advanced mass spectrometry solutions like UltraFAIMS. These products are employed in the diagnosis and monitoring of conditions like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced chemical detection. Through its subsidiary, Owlstone Medical, the company aims to lead the global market in non-invasive diagnostics for cancer, infectious, and inflammatory diseases, with a focus on breath-based diagnostic tools.

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds (VOCs) in breath, serving as biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA, disease biomarker detection tools such as Lonestar, and advanced mass spectrometry solutions like UltraFAIMS. These products are employed in the diagnosis and monitoring of conditions like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced chemical detection. Through its subsidiary, Owlstone Medical, the company aims to lead the global market in non-invasive diagnostics for cancer, infectious, and inflammatory diseases, with a focus on breath-based diagnostic tools.

Corner Therapeutics is a biotechnology research company focused on immunotherapy. It specializes in developing technologies that stimulate exceptional memory T cells to achieve lifelong immunity. The company utilizes a versatile dendritic cell hyperactivation platform that induces strong T-cell responses, aiming to provide robust and durable immunity against a wide range of cancers and infectious diseases. By enhancing T-cell activation, Corner Therapeutics seeks to enable healthcare providers to promote lasting immunity and optimize immune regulation.

Noze is a leader in digital odor perception technology, creating advanced solutions that replicate the human sense of smell. Their sophisticated digital nose utilizes a specialized sensor, developed with NASA technology, to detect and identify odors in various real-world environments. This technology collects and analyzes data through an AI engine, allowing healthcare providers to assess air quality, monitor chemical footprints, and potentially diagnose diseases based on breath-based odor biomarkers. By enabling real-time disease detection and routine health screenings with a single exhale, Noze aims to enhance human health and well-being while improving patient outcomes.

PhaSER Biomedical is Exploiting the 8HUM mouse, a unique mouse model with multiple utilities in drug discovery, and development.

ProteinLogic’s ImmiPrint® technology impacts the emerging market for diagnostic, predictive, prognostic and other biomarker applications.

Sail Biomedicines is a biotechnology company developing innovative medicines using circular RNA technology and programmable nanoparticles. Its platform, Endless RNA (eRNA), combined with unique, naturally-derived nanoparticles, enables the comprehensive programming of drugs, enhancing their potency and targeting capabilities. The company aims to transform patient care by leveraging artificial intelligence and advanced delivery systems to create first-in-class therapeutics.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Molecular Loop is a biotechnology company focused on DNA sequencing. It offers a unique approach to sequencing through its Molecular Loop targeting technology, which eliminates the need for a separate library preparation process. The company's method involves designing amplicons that tile across each target on both strands, providing sequence data with minimal additional work and cost. Molecular Loop also provides custom assays tailored to user specifications, alongside expanded and customizable carrier screening panels and SARS-CoV-2 research panels. This enables healthcare professionals and researchers to access efficient systems for production-scale targeted sequencing applications.

Naobios is a contract development and manufacturing organization (CDMO) located in Saint Herblain, France. The company specializes in bioprocess development and provides good manufacturing practice (GMP) production services for clinical batches of various biopharmaceutical products, including viral vaccines, oncolytic viruses, viral vectors, and challenge agents. Naobios assists clients in the development and optimization of processes necessary for generating live vaccine products, ensuring compliance with industry standards.

Philips, established in 1891, is a Dutch diversified technology company that focuses on improving people's health and well-being through meaningful innovation. The company operates in three segments: Diagnosis & Treatment, Connected Care, and Personal Health. Philips Healthcare, a division of Philips, is a leader in diagnostic imaging, image-guided therapy, patient monitoring, health informatics, consumer health, and home care. It offers a wide range of products such as CT scanners, MRI machines, ultrasound equipment, and more, aiming to enhance preventive care, diagnosis, and treatment. Additionally, Philips Research drives innovation across these segments, while the Philips Foundation focuses on reducing healthcare inequality through access to quality care for disadvantaged communities. The company also provides lighting solutions and consumer lifestyle products, including personal care and oral healthcare items.

Scentian Bio is a developer of innovative biosensor devices that integrate insect biology with nanotechnology to revolutionize sensing applications. The company's technology leverages insect odorant receptors to create biosensors for commercial use in the medical and food industries. By employing machine learning, these devices can detect volatile organic compounds, such as off-notes in food and beverages, as well as identify fraud and adulterants in raw materials. Scentian Bio aims to provide users with advanced sensing solutions that harness the power of nature, making it easier to understand and respond to complex chemical signals.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

EHA Clinics is dedicated to providing accessible, effective, and affordable healthcare services. The organization offers a comprehensive healthcare network that includes routine medical care, laboratory services, pharmacy, optometry, dental care, urgent care, and specialist consultations. EHA Clinics ensures that members have round-the-clock access to healthcare through various channels, including physical locations, telehealth virtual visits, and home care services. By leveraging technology and a skilled team, EHA Clinics aims to enhance the healthcare experience, improve patient outcomes, and offer competitive pricing for individual, family, and business members.

Bactolife is a company dedicated to addressing the global challenge of antimicrobial resistance through innovative solutions. Its proprietary Binding Protein ingredients are designed to strengthen the gut microbiome and minimize the risk of gastrointestinal infections in both humans and animals. By focusing on neutralizing harmful pathogens and their toxins while preserving beneficial microbes, Bactolife aims to enhance gut health and reduce reliance on traditional antimicrobials. The company's approach emphasizes the modulation of the gut microbiome to improve overall health outcomes, making a significant contribution to the fight against antimicrobial resistance. Through its developments, Bactolife seeks to empower individuals and communities worldwide in maintaining better health.

Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

Co-Diagnostics is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Latham BioPharm Group (LBG) specializes in providing comprehensive support for the life sciences sector, focusing on advancing programs through a range of services that include business development, program management, quality assurance, regulatory guidance, and strategic consulting. With a team averaging over 20 years of experience, many of whom have held senior positions in both private enterprises and the US government, LBG has a proven track record in biodefense, pandemic response, and product development. Over the past two decades, the firm has successfully helped clients secure more than $1 billion in government funding and over $100 million in licensing fees. Their services encompass critical business evaluations, market assessments, and assistance in obtaining funding, followed by effective program management to drive projects toward key milestones. By integrating expertise in vaccine, therapeutic, medical device, and diagnostic product development, LBG aids clients in achieving their organizational objectives efficiently and effectively.

Aegis Life is a biotechnology company focused on advancing nucleic acid delivery technology, specifically through its proprietary platform known as fusogenix PLV. This technology, developed over two decades, is designed to facilitate the rapid development and commercialization of vaccines and therapeutics aimed at preventing and treating infectious diseases. Aegis Life's innovative approach supports the pharmaceutical industry in accelerating the discovery, clinical development, and manufacturing processes for vaccines and treatments, particularly in response to emerging health threats such as COVID-19.

Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Osivax is a company focused on developing immunotherapy vaccines aimed at treating infectious diseases. Its innovative vaccines enhance the uptake into dendritic cells and boost the immunogenicity of natural proteins, which triggers a more effective immune response, particularly through significant CD8 T cell activation. This technology is designed to serve as a universal vaccine, targeting not only existing but also emerging coronavirus infections, as well as other globally impactful infectious diseases. In addition to infectious diseases, Osivax's vaccines also support cancer treatment, providing medical practitioners with advanced tools to treat a range of serious health conditions effectively.

SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines using a proprietary technology known as molecular superglue. This platform allows for the rapid creation of bonding vaccines by attaching antigens to viruses and other particles, enhancing the vaccine development process. By leveraging this unique approach, SpyBiotech aims to provide medical institutions and research centers with more effective vaccines that can be developed in a shorter timeframe, ultimately improving immunity against various diseases, including bacterial infections.

DelSiTech, Ltd. is a technology specialist based in Turku, Finland, focused on developing and licensing long-term controlled drug delivery systems. Established in 2001, the company specializes in biodegradable silica-based implants and injectable formulations for the controlled release of small molecular drugs, biopharmaceuticals, and viral vectors. DelSiTech's innovative technology embeds active ingredients within a silica matrix, facilitating parenteral and local administration through injectable depot, implant, and eye drop dosage forms. By providing expertise in controlled release products, DelSiTech aims to address various drug-related challenges and support clients in the development of supergeneric solutions.

Noze is a leader in digital odor perception technology, creating advanced solutions that replicate the human sense of smell. Their sophisticated digital nose utilizes a specialized sensor, developed with NASA technology, to detect and identify odors in various real-world environments. This technology collects and analyzes data through an AI engine, allowing healthcare providers to assess air quality, monitor chemical footprints, and potentially diagnose diseases based on breath-based odor biomarkers. By enabling real-time disease detection and routine health screenings with a single exhale, Noze aims to enhance human health and well-being while improving patient outcomes.

MIP Discovery is a technology leader specializing in the development of molecularly imprinted polymers (MIPs) and nanoMIPs, which are plastic antibodies designed to address the limitations of traditional MIP manufacturing methods. The company's innovations feature polymers and antibodies that incorporate a single binding site for specific targets, allowing them to be effectively fused to solid substrates, such as sensor surfaces. This capability provides hospitals with highly effective reagents suitable for a variety of applications, including point-of-care diagnostics and field-based testing, thereby enhancing the efficiency and accuracy of medical testing.

UW Medicine is a clinical research and healthcare system that provides a higher degree of healthcare for pre-med students. UW Medicine health professionals provide the most up-to-date care for each individual patient through these integrated programs, lead one of the world's largest and most comprehensive medical research programs, and provide innovative learning programs for students, trainees, and practitioners in the health professions. UW Medicine, as the region's only comprehensive clinical, research, and learning health system, provides a higher level of healthcare, ranging from primary and preventive care to the most highly specialized care for the most complex medical conditions.

VisualDx is a clinical decision support system that aims to improve diagnostic accuracy and patient safety in healthcare settings. By integrating a curated medical image library with a robust search engine, it provides clinicians with patient-specific answers swiftly, facilitating informed therapeutic decisions. The platform encompasses high-quality images covering a range of both pediatric and adult medical conditions. Used by over 2,300 hospitals, clinics, and medical schools globally, VisualDx enhances point-of-care decisions and fosters better patient engagement, enabling healthcare providers to deliver timely and effective care.

Aspen Pharmacare Holdings Limited is a global specialty pharmaceutical company headquartered in Durban, South Africa. It manufactures and supplies a diverse portfolio of specialty, branded, and generic pharmaceutical products across more than 150 countries. The company operates through two main segments: Commercial Pharmaceuticals and Manufacturing. Aspen offers a range of products, including general anaesthetics, muscle relaxants, cytotoxic medicines, and injectable anticoagulants, with a focus on low molecular weight heparins. Additionally, Aspen engages in the contract manufacturing and supply of active pharmaceutical ingredients and finished dose pharmaceuticals for third parties. The company's extensive product offerings include oral solids, injectables, liquids, semi-solids, and biologicals. With a strong presence in various international markets, including Africa, Asia, Europe, and the Americas, Aspen continues to expand its operations through strategic acquisitions and partnerships. Founded in 1850, Aspen has established itself as a leading player in the pharmaceutical industry.

Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, specializing in DNA therapies and technology. Founded in 2007, it has developed the proTL synthetic DNA platform, which allows for the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach supports various applications, including veterinary vaccines, monoclonal antibodies, cancer and gene therapies, allergy treatments, RNA interference therapies, and stem cell reprogramming. The company boasts a skilled scientific and drug development team, led by founder and CEO Jonny Ohlson, and includes experienced professionals such as Clive Dix and John Tite. Touchlight has established partnerships with several leading academic institutions, including Imperial College London and the University of Pennsylvania, to advance its research and development efforts. The company has successfully patented its synthetic DNA platform and demonstrated therapeutic proof-of-principle through collaboration with these academic partners.

Helium Health is a technology company focused on transforming healthcare in Africa by providing a comprehensive suite of software solutions for hospitals and clinics. The company specializes in electronic health record systems that facilitate the management of patient data and hospital operations. Its platform simplifies various processes, including doctor visits, prescriptions, and medical billing, making it accessible from any device. Additionally, Helium Health offers customizable forms and tools for monitoring healthcare trends, generating alerts, and producing reports. By leveraging technology, the company aims to create a modern and affordable healthcare system while aspiring to become the largest healthcare data exchange in Africa.

Adapsyn Bioscience Inc. is a biotechnology company based in Hamilton, Canada, focused on the discovery and development of novel medicines derived from organic biomolecules, particularly those produced by microorganisms. Founded in 2016, the company utilizes an advanced bioinformatics platform that incorporates proprietary algorithms and artificial intelligence to analyze genomic and metabolomic data. Its key products include various tools such as PRISM, which identifies biosynthetic gene clusters in microbial genomes; GARLIC, which defines gene clusters for natural product drug variants; the GRAPE algorithm, which reveals evolved drug fragments; and CLAMS, which matches gene clusters to compounds identified through mass spectrometry. By leveraging these innovative technologies, Adapsyn aims to uncover small molecules with unique biological activities, thereby enhancing drug discovery efforts in the biotechnology and pharmaceutical sectors.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

Bactolife is a company dedicated to addressing the global challenge of antimicrobial resistance through innovative solutions. Its proprietary Binding Protein ingredients are designed to strengthen the gut microbiome and minimize the risk of gastrointestinal infections in both humans and animals. By focusing on neutralizing harmful pathogens and their toxins while preserving beneficial microbes, Bactolife aims to enhance gut health and reduce reliance on traditional antimicrobials. The company's approach emphasizes the modulation of the gut microbiome to improve overall health outcomes, making a significant contribution to the fight against antimicrobial resistance. Through its developments, Bactolife seeks to empower individuals and communities worldwide in maintaining better health.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

SwipeRx is a digital platform designed to enhance the operations of pharmacies by connecting pharmaceutical manufacturers, pharmacies, and patients. It offers a range of services, including specialized healthcare logistics, negotiated pricing, and financing solutions, creating a robust network for pharmacy purchasing. The platform generates insights that facilitate collaboration with pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and enhances daily operational efficiencies. By providing real-time access to patient and sell-out data, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.

Yemaachi Biotechnology is focused on advancing the diagnosis and treatment of cancer through innovative therapeutic technologies. The company employs immunogenomics, bioinformatics, and artificial intelligence to enhance the development of effective cancer detection and treatment strategies. By leveraging these advanced methodologies, Yemaachi aims to lower the economic burden of cancer and improve patient outcomes through more accurate and efficient therapeutic solutions.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Aridis Pharmaceuticals is a late-stage biopharmaceutical company based in San Jose, California, founded in 2003. The company specializes in discovering and developing targeted immunotherapy treatments using fully human monoclonal antibodies (mAbs) to combat life-threatening infections. Its lead product candidate, AR-301, is currently in Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis Pharmaceuticals is advancing several other mAb candidates through various stages of clinical development, including AR-105 and AR-101 for gram-negative bacterial infections, AR-401 for Acinetobacter baumannii infections, AR-201 for respiratory syncytial virus, and AR-501 for chronic lung infections in cystic fibrosis patients. The company employs proprietary technology platforms to rapidly identify and manufacture these mAbs from patients who have successfully overcome infections, leveraging the natural potency of the human immune system.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Elarex, a Canadian healthcare technology company, specializes in developing and commercializing proprietary formulation technologies. Its flagship innovation, PT120, stabilizes biologicals, including live vaccines, enabling them to maintain full efficacy even when stored at 40°C, comparable to -80°C storage. This breakthrough allows for broader access to vaccines and biological drugs by facilitating transportation and storage in diverse environments, thereby enhancing global healthcare accessibility.

Providence Therapeutics Inc. is a biotechnology company based in Toronto, Canada, founded in 2015. The company specializes in the development and production of messenger ribonucleic acid (mRNA) vaccines formulated in lipid nanoparticles. Its portfolio includes PTX-101, a personalized mRNA cancer vaccine aimed at treating advanced ovarian cancer, and various COVID-19 vaccines, including PTX-COVID19-B and PTX-COVID19-T, which target the coronavirus and elicit immune responses against the virus. Providence Therapeutics is committed to creating safe and effective therapies to address unmet medical needs, particularly in oncology and infectious diseases, thereby enhancing the quality of life for patients.

Philips, established in 1891, is a Dutch diversified technology company that focuses on improving people's health and well-being through meaningful innovation. The company operates in three segments: Diagnosis & Treatment, Connected Care, and Personal Health. Philips Healthcare, a division of Philips, is a leader in diagnostic imaging, image-guided therapy, patient monitoring, health informatics, consumer health, and home care. It offers a wide range of products such as CT scanners, MRI machines, ultrasound equipment, and more, aiming to enhance preventive care, diagnosis, and treatment. Additionally, Philips Research drives innovation across these segments, while the Philips Foundation focuses on reducing healthcare inequality through access to quality care for disadvantaged communities. The company also provides lighting solutions and consumer lifestyle products, including personal care and oral healthcare items.

Inventprise is a biotechnology company based in Redmond, Washington, focused on developing vaccines to combat infectious diseases. Established in 2012, the company is known for its 25-valent pneumococcal conjugate vaccine (PCV), which is supported by significant funding from the Bill and Melinda Gates Foundation, exceeding $100 million. This vaccine is specifically designed for large-scale distribution in low- and middle-income countries. In addition to vaccine development, Inventprise offers comprehensive contract manufacturing and development services, including quality control assays, batch records, and training. The company also operates a fully equipped quality control laboratory that conducts testing for identity, potency, purity, and stability, thereby assisting clients in addressing health disparities and promoting public health.

Reithera Srl is a company devoted to develop and produce biopharmaceutical products based on gene delivery technologies for advanced therapies, in order to prevent and treat several serious or life-threatening diseases.

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing proprietary therapeutics for chronic diseases through its innovative ProNeura long-term drug delivery platform. The company's key product, Probuphine, is the first slow-release implant formulation of buprenorphine, designed to provide stable medication levels for up to six months, thereby enhancing patient compliance in the treatment of opioid dependence. Titan also develops ProNeura-Ropinirole, an implant for delivering ropinirole to treat Parkinson's disease, and a similar implant for managing hypothyroidism. The ProNeura technology holds promise for addressing various chronic conditions by ensuring consistent drug delivery, which can improve patient outcomes. In December 2012, Titan entered a licensing agreement granting Braeburn Pharmaceuticals exclusive commercialization rights to Probuphine in the U.S. and Canada, receiving significant financial incentives tied to regulatory approvals and sales milestones. Additionally, Titan receives royalties from the sales of Fanapt, an atypical antipsychotic, further supporting its development efforts.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing rapid diagnostic tests for epidemic fever viruses, including dengue, chikungunya, and Zika. Founded in 2018, the company specializes in paper-based diagnostic systems that enable swift detection of viral antigens produced during infections. Its innovative platform allows for real-time data reporting through a mobile application, which captures results along with information on test timing and location. This approach aims to facilitate epidemiologic predictions and disease mapping, ultimately assisting governments and health organizations in managing outbreaks effectively and preventing public health crises. E25Bio's solutions are designed to provide affordable and timely diagnostics at the point of care.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

HJF Medical Research International is an NGO that supports international programs advancing medical research and HIV prevention.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, focused on enhancing global health outcomes through early disease detection. The company has developed a proprietary technology platform that enables the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This platform facilitates the analysis of native-state biomarkers and nanoparticles, supporting multiomics applications. Biological Dynamics specializes in cancer detection and offers a range of services, including the TR(ACE) Assay for monitoring treatment responses and tumor burdens, as well as liquid biopsy testing for personalized medicine. Additionally, the company provides clinical laboratory services, including molecular and next-generation sequencing, and has programs aimed at drug development in areas such as Alzheimer's disease. Founded in 2008, Biological Dynamics is committed to utilizing machine learning and its advanced technology to address various health challenges, including autoimmune diseases, transplant rejection, and traumatic brain injury.

VisualDx is a clinical decision support system that aims to improve diagnostic accuracy and patient safety in healthcare settings. By integrating a curated medical image library with a robust search engine, it provides clinicians with patient-specific answers swiftly, facilitating informed therapeutic decisions. The platform encompasses high-quality images covering a range of both pediatric and adult medical conditions. Used by over 2,300 hospitals, clinics, and medical schools globally, VisualDx enhances point-of-care decisions and fosters better patient engagement, enabling healthcare providers to deliver timely and effective care.

Almac Group is a contract development and manufacturing organization that provides a comprehensive range of services to pharmaceutical and biotech companies worldwide. Established over 40 years ago and privately owned, the company specializes in research and development, biomarker discovery, active pharmaceutical ingredient (API) manufacturing, formulation development, clinical trial supply, and companion diagnostic development. Headquartered in Craigavon, Northern Ireland, Almac operates additional facilities in the UK, Ireland, the US, and Asia. With a workforce exceeding 4,500 employees, the company is committed to continuous investment in its service offerings, including advancements in biomarker and companion diagnostics, clinical trial data management, and biocatalytic API manufacturing. Almac Discovery, a division of the group, is dedicated to the research and development of innovative cancer treatments, focusing on early-stage partnerships for further program development.

Landcent is a company dedicated to combating global infectious diseases, with a focus on malaria. It develops and delivers affordable, sustainable solutions that are safe for large-scale use, aiming to accelerate the fight against these diseases and ultimately eliminate them.

MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.

RJH Biosciences is a biotechnology company specializing in the development of transfection reagents and delivery systems designed to transport various types of nucleic acids into human cells and cell lines. The company emphasizes innovative solutions for addressing blood cancers and modifying immune cells, thereby enhancing the therapeutic potential of nucleic acids in medical applications. RJH Biosciences distributes its products through its website and is also engaged in projects aimed at developing new medical treatments.

One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.

Enesi Pharma is an innovative pharmaceutical company developing novel products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare. The company’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organizations.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, founded in 2016. It connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its services. Users can engage with medical professionals via video calls, voice calls, and chat, making healthcare more accessible. The platform also allows patients to order laboratory tests that can be conducted at home. Additionally, HaloDoc helps users locate the nearest hospitals and clinics, streamlining the process of obtaining medical advice and services in real-time.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, focused on enhancing global health outcomes through early disease detection. The company has developed a proprietary technology platform that enables the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This platform facilitates the analysis of native-state biomarkers and nanoparticles, supporting multiomics applications. Biological Dynamics specializes in cancer detection and offers a range of services, including the TR(ACE) Assay for monitoring treatment responses and tumor burdens, as well as liquid biopsy testing for personalized medicine. Additionally, the company provides clinical laboratory services, including molecular and next-generation sequencing, and has programs aimed at drug development in areas such as Alzheimer's disease. Founded in 2008, Biological Dynamics is committed to utilizing machine learning and its advanced technology to address various health challenges, including autoimmune diseases, transplant rejection, and traumatic brain injury.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

DelSiTech, Ltd. is a technology specialist based in Turku, Finland, focused on developing and licensing long-term controlled drug delivery systems. Established in 2001, the company specializes in biodegradable silica-based implants and injectable formulations for the controlled release of small molecular drugs, biopharmaceuticals, and viral vectors. DelSiTech's innovative technology embeds active ingredients within a silica matrix, facilitating parenteral and local administration through injectable depot, implant, and eye drop dosage forms. By providing expertise in controlled release products, DelSiTech aims to address various drug-related challenges and support clients in the development of supergeneric solutions.

Lyell Immunopharma Inc is a clinical-stage cell therapy company focused on developing innovative treatments for patients with solid tumors through T cell reprogramming. The company aims to overcome significant challenges in adoptive T cell therapy, specifically T cell exhaustion and loss of durable stemness, which impede effective and lasting responses in cancer treatment. Utilizing its proprietary platforms, Gen-R and Epi-R, Lyell is working to enhance the proliferative capacity, self-renewal, and differentiation abilities of T cells. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, all designed to deliver improved and potentially curative outcomes for patients suffering from solid tumors.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Evolve Biosystems, Inc. is a biotechnology company based in Davis, California, focused on developing and marketing probiotic-based biotherapeutics aimed at establishing, restoring, and maintaining a healthy human microbiome. The company specializes in addressing gut dysbiosis across the human life cycle, particularly in newborns during their first six months of life. Evolve Biosystems utilizes a platform that combines specific probiotic bacteria with prebiotic oligosaccharides to create effective delivery systems. Their products include consumer-directed solutions for home use as well as specialized formulations for neonatal intensive care units. In addition to human health, the company also applies its discovery platform to address similar microbiome issues in production animals. Evolve Biosystems was incorporated in 2011.

Scripps Research, established in 1924, is a prominent, not-for-profit biomedical research institution with campuses in La Jolla, CA, and Jupiter, FL. Employing around 3,000 people, it's renowned for its contributions to science and health, including breakthroughs in cancer, rheumatoid arthritis, and hemophilia treatments. The institute, which ranks among the top ten for its graduate program in biology and chemistry, is led by distinguished scientists, including Nobel laureates. Its drug discovery and development division, Calibr, collaborates with scientists to expedite the delivery of innovative medicines to patients. Scripps Research is recognized as a leader in biomedical innovation, ranking No.1 by the Nature Index.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

PnuVax Incorporated is dedicated to the production of high quality biopharmaceuticals for the promotion of public health worldwide. Their team has over 30 years of experience in the pharmaceutical industry, from research to full scale production.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.